QNCX QNCX
Company Profile ↓Company Overview
QNCX (QNCX) is a publicly traded company listed on with a market capitalization of $8.05M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.03.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -91.14% |
| 6 Months: | -0.41% |
| 3 Months: | +17.40% |
| 1 Month: | +65.03% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)83.06 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 96.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 83 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.93M | 9.89M | 11.36M | 16.24M | 11.11M |
| Operating Income | -2.76M | -2.64M | -2.87M | -6.08M | -9.57M | -10.57M | -17.86M | -18.27M | -21.91M | -23.31M | -21.78M | -21.68M | -21.86M | -16.26M | -7.62M | -12.96M | -5.58M | -6.09M | -11.22M | -28.19M | -5.86M | -12.93M | -9.89M | -11.36M | -16.24M | -11.11M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -12.90M | -9.86M | -11.33M | -16.20M | -11.08M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -14.98M | -15.98M | -13.49M | -36.31M | 30.57M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 47.00K | 67.00K | -46.00K | 3.15M | -5.34M |
| Net Income | -3.38M | -3.11M | -2.52M | -5.68M | -9.06M | -9.86M | -17.18M | -17.61M | -21.51M | -23.09M | -21.75M | -21.71M | -21.64M | -16.56M | -7.92M | -12.25M | -4.89M | -5.35M | -11.15M | -27.73M | -5.49M | -15.03M | -16.05M | -13.44M | -39.46M | 35.91M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.74 | -0.73 | -0.72 | -0.51 | -0.22 | -0.34 | -0.14 | -0.15 | -0.26 | -0.64 | -0.13 | -68.40 | -68.00 | -50.00 | - | 57.60 |
| R&D Expense | 2.41M | 2.29M | 2.29M | 4.83M | 7.11M | 8.25M | 14.38M | 14.09M | 16.98M | 16.82M | 14.72M | 14.04M | 12.76M | 7.20M | 2.45M | 3.23M | 1.35M | 1.43M | 3.70M | 4.15M | 4.92M | 8.14M | 6.55M | 8.08M | - | 6.84M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 51.19M | 27.14M | 36.17M | 50.43M |
| Operating Income | -12.12M | -39.17M | -78.89M | -90.32M | -51.19M | -27.14M | -36.17M | -50.43M |
| EBITDA | - | - | - | - | -50.99M | -26.82M | -35.98M | -50.29M |
| Interest Expense | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | -51.94M | -31.58M | -56.74M | -80.77M |
| Tax Provision | - | - | - | - | -284.00K | -197.00K | 87.00K | 3.21M |
| Net Income | -12.48M | -36.98M | -76.85M | -89.94M | -51.66M | -31.39M | -56.83M | -83.98M |
| Diluted EPS | - | - | - | -3.03 | -308.00 | -168.00 | -262.00 | -336.00 |
| R&D Expense | 10.09M | 30.21M | 61.31M | 60.80M | 25.18M | 9.45M | 18.59M | 35.38M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 72.88M | 124.37M | 189.47M | - | 103.91M | 167.90M | 114.48M | 93.52M |
| Current Assets | - | - | - | - | - | 93.75M | 77.44M | 44.04M | 22.90M |
| Cash & Equivalents | - | 24.87M | 51.21M | 133.80M | - | 44.58M | 20.75M | 6.21M | 5.81M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | 1.00M | 993.00K | 882.00K | 3.62M |
| Total Liabilities | - | 1.46M | 8.89M | 17.20M | - | 3.32M | 82.82M | 84.33M | 129.24M |
| Current Liabilities | - | 1.46M | 8.89M | 17.00M | - | 3.07M | 9.57M | 7.28M | 43.23M |
| Long Term Debt | - | - | - | - | - | - | 13.43M | 14.32M | - |
| Total Debt | - | - | - | - | - | 453.00K | 13.81M | 14.81M | 18.47M |
| Total Equity | -20.28M | -32.63M | 115.48M | 172.26M | - | 100.59M | 85.08M | 30.15M | -35.71M |
| Shares Outstanding | - | - | - | - | - | 180.68K | 214.87K | 220.01K | 278.63K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -11.70M | -33.28M | -50.82M | - | -44.04M | -18.29M | -31.90M | -41.42M |
| Investing Cash Flow | -46.75M | -17.75M | -52.43M | - | 18.00M | -5.76M | 21.91M | 23.23M |
| Financing Cash Flow | 75.93M | 77.37M | 118.88M | - | 707.00K | 143.00K | -4.78M | 17.91M |
| Capital Expenditure | -212.00K | -55.00K | -52.00K | - | -133.00K | -160.00K | -257.00K | -352.00K |
| Free Cash Flow | -11.91M | -33.33M | -50.87M | - | -44.17M | -18.45M | -32.16M | -41.78M |
| Net Change in Cash | - | - | - | - | -25.33M | -23.91M | -14.77M | -289.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - |
| ROE % | 38.2% | -32.0% | -44.6% | - | -51.4% | -36.9% | -188.5% | 235.1% |
| ROCE % | -17.0% | -33.9% | -45.7% | - | -50.8% | -17.1% | -33.7% | -100.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for QNCX
Quince Therapeutics (QNCX) sees Squadron group report 5.6% ownership stake - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxQR3RhTkM5RU9OUkcwdWpXcmdROTRxaWNPYU1Qc3B4Z052UXhHalVCNzBsWFV1U09JX2l5MG0tamRoN0Yxc3JLOHZBOVpLYWpiampOQUJFZ2tKNG5BVmtCYVFWRGlFbGVSckFDaHNoSF9ndXZIX3J6R0pfcy1BZmlCNkZMckthaVRlSHMxUV…
QNCX Stockholders Plan to Sell 15.47M Shares Amid Unprofitable B - GuruFocus
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxQQk1kZ05YMHRDUTdhU0NwRklBcXE5YnJBaUtGNnljT1hLYzYwMHZEckNrNFZKWGFjVjdiY3VwZ2o5VEFiaEY1QVp1M1lEaGtFeXdYbDJsMENVUF83TUlJQWJ5M3RST2xfRHgzTjE1bTFkY2N3NC1pbWtsYWxOYlRLdGdod0NBSFZfTHphcH…
Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNOUtOSnVlWmpxTWFENldWRWF4R0FmS2ozNUx1QjgtdUZ4Nnh3dnhIRDFYZWVhalEtM0RES3dhbzFVd1VPMEZ5aENyTGgyRlloUUdBam84cWthZDBkcmZZUWZOemNMUElHMUNoLWxHU1hLYkVLbWZnM0VtUHFHeHdPblE1RmtUVmNiVFRNSG…
Quince Therapeutics Announces Leadership Transition to Orphai Team - theglobeandmail.com
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxQRVkxOW5kQnZxZ0JTUzJGNTByTjlpbTZ6MzJkbmxaa0VkcFYtM0h6eGFqRVBGTHJ0REFFaTlxTUhxSmk0SU0wZXJ0MmhLMFBVd1J0YmN6YWZ1a3k4QkNnV0Z4amFraXhEVnpUN0ZzbGdlMGxDV2phLUtfcUg0QVVkbTY0dmNhZ053Nmpwb0…
Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOazJIb0M3cWZ2YUxoQV9SVkd1aVNkU3hIV1hiY1ZWaDlQTllwS1ZSdFQycVRrZHRrU3N3dHNKY3p3RGFQcUFLbk9Kak5YVndDRWNSU3czQWhlSVJxOEFKa3ZqaVc5N1IxRmRuYjFoNFpFRTJ6NnhjZG1rd3d5aEdxSXdUamdEWHlzWURJbG…
$QNCX stock is up 11% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNY19nUFlKUVFQb0J1bzMtakNTUUgzb3hlcUU4ajd4SUl3QzdKQW1OYi1jRFdvZ2hLWFdSOU1jcldlZENfZHpDN3pPNzJVVEVLeDlnMFFhbVhLNkpONTVQVlVQakhFQk0xdFhmSzVZVTV2Q0dUYmJKeEh3NjZBOTNvM3ZuNTV4TXJTaWI4aX…
QNCX — Frequently Asked Questions
What is the current share price of QNCX?
As of 2026-08-05 17:25 PDT, QNCX trades at $28.88 on NASDAQ/NYSE. Its 52-week range is $16.00 to $880.00.
What is the market capitalisation of QNCX?
QNCX has a market capitalisation of $8.05M on NASDAQ/NYSE.
What is the P/E ratio of QNCX?
QNCX trades at a trailing price-to-earnings (P/E) ratio of -0.09. Its price-to-book (P/B) ratio is -0.23.
Is QNCX a good stock to buy?
This page provides a data-driven analysis of QNCX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.